Steven Pipe, MD: Changing the Delivery of Bleeding Prevention for Hemophilia Patients
Dr. Pipe, a speaker in the Special Education Session on Newly Approved Drugs, reviews what clinicians need to know about coagulation factor IX (recombinant)/antihemophilic factor (recombinant) as bleeding prophylaxis in patients with hemophilia.
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on all LentiGlobin gene therapy trials following an announcement that two participants...
Melphalan flufenamide, in combination with dexamethasone, has received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients...
The U.S. Food and Drug Administration (FDA) has approved trilaciclib, a cyclin-dependent kinase 4/6 inhibitor, to reduce the frequency of bone marrow suppression in...
Novartis and the Bill and Melinda Gates Foundation are collaborating on a one-step, one-time gene therapy for patients with sickle cell disease (SCD). The...